Due to a joint recommendation of the US Centers for Disease Control and Prevention and the US Food and Drug Administration, ECMC is temporarily suspending the administration of the Johnson & Johnson COVID-19 vaccine. While 6.8 million doses of the Johnson & Johnson COVID-19 vaccine have been administered in the US, six cases of a “rare and severe” type of blood clot have been reported in women between the ages of 18 and 48. The CDC and the FDA stated that the symptoms occurred 6 to 13 days after vaccination. Anyone who received the Johnson & Johnson COVID-19 vaccine and develops symptoms of severe headache, stomach or abdominal pain, leg pain or shortness of breath within three weeks of their vaccination should contact their health care provider.

All scheduled Johnson & Johnson COVID-19 vaccinations at ECMC are temporarily suspended. **Anyone scheduled to receive the Johnson & Johnson vaccine will be immediately rescheduled to receive a Pfizer vaccine.** All Pfizer and Moderna vaccinations will continue as scheduled.

For additional information please contact 716-898-3844 or go to [https://www.ecmc.edu/health-services-and-doctors/covid-19/ecmc-covid-19-vaccine-center/](https://www.ecmc.edu/health-services-and-doctors/covid-19/ecmc-covid-19-vaccine-center/)

The joint CDC/FDA statement said, “CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.”